Authorize Bonds for Immunology Research

This statute proposes a state general obligation bond of approximately $5.5 billion to fund advanced research into immunology at California universities, medical centers, and research institutes. The funding would support scientific studies aimed at understanding and treating various diseases through the immune system, including autoimmune disorders, cancer immunotherapy, infectious disease resistance, and age-related immune decline. Gary Michelson, a retired orthopedic surgeon and philanthropist based in Los Angeles, has personally contributed significant seed funding to the signature-gathering effort required to qualify the measure for the November 2026 ballot. The bond would be repaid over 30 years through the state’s General Fund, with total repayment costs including interest estimated at approximately $8.5 billion by the Legislative Analyst’s Office. An independent oversight committee appointed by the Governor, the Speaker of the Assembly, and the Senate Rules Committee would be responsible for allocating grants and ensuring that funded research meets scientific rigor and public accountability standards. At least 40 percent of the bond proceeds would be directed to clinical and translational research with the goal of moving laboratory discoveries into treatments available to patients within a defined timeline. The proposal includes provisions requiring that therapies and technologies developed with bond-funded research be made accessible to California residents at reasonable cost, though the enforcement mechanism for this provision has drawn scrutiny from legal analysts. Supporters including the California Institute for Regenerative Medicine, several University of California chancellors, and patient advocacy organizations argue that the investment would position California as the global leader in immunology research and generate substantial economic returns through job creation and commercialization. Opponents including the Howard Jarvis Taxpayers Association have criticized the proposal as an expensive commitment that adds to the state’s already substantial debt burden, currently exceeding $80 billion in outstanding general obligation bonds. Some fiscal policy analysts have suggested that a pay-as-you-go appropriation through the annual budget process would be a more prudent approach than bonding, though supporters counter that the scale of investment required exceeds what annual budgets can reliably sustain. The proposal draws on the precedent of Proposition 71, approved by California voters in 2004, which authorized $3 billion in bonds for stem cell research and led to the creation of the California Institute for Regenerative Medicine. If approved, the first tranche of bond funding would be available for grant applications beginning in fiscal year 2027-28, with the oversight committee required to issue its first round of awards within 12 months of the measure taking effect.